Anthropic is building a team to design its own in-house AI chips as it faces surging demand for its models, Business Insider reports
Newsquawk Staff ·
Anthropic is building a team to design its own in-house AI chips as it faces surging demand for its models, Business Insider reports.
What it means
A frontier model developer moving toward in-house silicon follows a well-worn path: the large cloud platforms each took years to stand up custom accelerator programmes, and those efforts tended to supplement rather than displace merchant chip purchases, with external supply remaining the marginal source of capacity through each demand cycle. The distinction worth drawing is between a hiring signal, which this is, and a tape-out or production commitment; the former is cheap to announce and historically precedes any volume impact by a multi-year lag. The read-across runs through two channels: the merchant accelerator complex, where such headlines have repeatedly weighed on sentiment before order books showed any actual share shift, and the hyperscalers and foundries that would manufacture any custom part, since in-house designs still route through the same fabrication and advanced packaging capacity. The tells to follow are whether the company pursues a full custom design or a co-design arrangement with an existing silicon partner, and whether its compute supply agreements with its cloud backers change in character. As a single-sourced report of a team build-out, this sits at the earliest and least binding end of the precedent range.
Sources
- American Express (AXP) Q3 2026 (USD): EPS 5.42 (exp. 4.50), Revenue 20.1bln (exp. 20.1bln)
- Booz Allen (BAH) Q2 2026 (USD): Adj. EPS 1.76 (exp. 1.48), Revenue 2.80bln (prev. 2.81bln)
- SLB (SLB) Q3 2026 (USD): adj. EPS 0.64 (exp. 0.62), Revenue 9.45bln (exp. 9.27bln)
- Nvidia (NVDA) launches Minerva platform for end-to-end AI factory observability
- US EQUITY OPEN: Mag-7 earnings lead Tech and Indices lower as the Middle East situation remains fragile
Related headlines
- Citi (C) has been granted approval by China for its securities unit3 hours ago
- Tesla (TSLA) has decided not to proceed with plans to produce Cybertruck for Australia and New Zealand11 hours ago
- OpenAI trims valuation target to USD 1.25tln after previously pitching a higher price, according to FT13 hours ago
- Newmont (NEM) says production growth is expected to begin in 2027 following previously flagged 2026 trough, adds Q3 gold production was broadly flat sequentially as anticipated14 hours ago
- SpaceX (SPCX) in talks to access 80,000 cell sites for new network14 hours ago
- Google (GOOG) announces general availability of an Anthropic-managed deployment option for Claude models on Google Cloud14 hours ago
- OpenAI is raising up to USD 30bln in funding round at a USD 1.25tln valuation, led by UAE investors, according to CNBC, citing sources; OpenAI is negotiating a commercial deal that would secure more computing capacity from the UAE15 hours ago
- Gilead Sciences (GILD) entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited; deal valued at USD 1.27bln in upfront cash15 hours ago
- Newmont (NEM) Q3 2026 (USD): Adj. EPS 2.20 (exp. 2.06), Revenue 6.36bln (exp. 6.30bln), Adj. EBITDA 3.95bln (exp. 3.73bln)15 hours ago
- Bloom Energy (BE) Q3 2026 (USD): Adj. EPS 0.94 (exp. 0.69), Revenue 1.24bln (exp. 1.06bln)15 hours ago
- Western Digital (WDC) Q1 2027 (USD): Adj. EPS 4.64 (exp. 4.08), Revenue 4.38bln (exp. 4.14bln)15 hours ago
- Merck & Co (MRK) and Moderna (MRNA) say safety profile of Intismeran plus Keytruda was generally consistent with previously reported studies of combination; significantly reduced the risk of recurrence or death by 42% compared to Keytruda alone17 hours ago
- DataDog (DDOG) recently offered almost USD 4bln to acquire Upwind Security, but the Co. hasn't accepted the offer, reports The Information citing sources18 hours ago
- Statnews posts on X, "Rumors are swirling that the Treasury Department this week is going to propose a rule that restricts U.S. investment in the Chinese biotech sector"18 hours ago
- Moderna (MRNA) downside attributed to early data leaks (link below) - UNCONFIRMED18 hours ago